HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Stephen D. Cassivi Claude Deschamps Mark S. Allen Francis C. Nichols, III Peter C. Pairolero Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shen, K. R. Articles by Pairolero, P. C. Search for Related Content PubMed PubMed Citation Articles by Shen, K. R. Articles by Pairolero, P. C.

J Thorac Cardiovasc Surg 2006;132:755-762
© 2006 The American Association for Thoracic Surgery

General Thoracic Surgery

Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: A 26-year experience with Siewert type III tumors

^a Division of General Thoracic Surgery, Mayo Clinic College of Medicine, Rochester, Minn
^b Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn

Received for publication April 12, 2005; revisions received April 10, 2006; accepted for publication May 12, 2006.

^_* Address for reprints: Stephen D. Cassivi, MD, Division of General Thoracic Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905. (Email: cassivi.stephen{at}mayo.edu).

Objective: A paucity of outcome data exists regarding patients with proximal stomach cancer involving the distal esophagus (Siewert type III tumors). This is especially true with regard to long-term survival rates after surgical intervention.

Methods: Medical records were reviewed of all patients who underwent total gastrectomy and distal esophagectomy with Roux-en-Y esophagojejunostomy for Siewert type III tumors from January 1975 through December 2000.

Results: There were 116 patients (93 men and 23 women). The median age was 66 years (range, 22-87 years). Pathologic stage was 0 (carcinoma in situ) in 1 patient, IB in 13 patients, II in 17 patients, IIIA in 34 patients, IIIB in 10 patients, and IV in 41 patients. Complete resection was achieved in 69 (59.5%) patients. Eleven (9.5%) patients were treated with neoadjuvant therapy, 49 (42.2%) received adjuvant therapy, and 6 (5.2%) received intraoperative radiation. Follow-up was complete in 114 (98.3%) patients, ranging from 1 to 281 months (median, 14 months). Operative mortality was 5.2%. Complications occurred in 51 (43.9%) patients. Clinically significant anastomotic leaks occurred in 15 (12.9%) patients. Median hospitalization was 13 days (range, 8-70 days). Median follow-up was 14 months (range, 1-281 months). Overall median survival was 434 days, with 1-, 5-, and 10-year survivals of 56.2%, 19.0%, and 13.5%, respectively. The only factor associated with increased hospital mortality was anastomotic leakage (P = .002). Incomplete resection, increased tumor stage and grade, and splenic involvement significantly worsened long-term survival.

Conclusions: Total gastrectomy and distal esophagectomy for Siewert type III tumors is associated with reasonable mortality and significant morbidity. Although often palliative, surgical intervention can provide long-term survival, especially in patients with completely resected, early-stage, low-grade tumors.